THIOACETAZONE
Please note thioacetazone is not licensed for the treatment of tuberculosis in the UK.
Thioacetazone is not usually recommended for the treatment of MDRTB. When it is used, it should be counted as half a drug in a treatment regimen.
DOSAGE
Adults: 150mg once daily.
Children: No information.
PREPARATIONS
Not currently available in the UK.
DRUG LEVEL MONITORING
· Drug levels need not be routinely measured.
ADVERSE EFFECTS
COMMON:
Dermatological: Rash (3%).
Gastrointestinal: Nausea, vomiting, diarrhoea, anorexia & dyspepsia.
Neurological: Giddiness (10%).
SERIOUS:
Haematological: Neutropaenia, anaemia, thrombocytopaenia; rarely: haemolytic anaemia, agranulocytosis, aplastic anaemia.
Hepatic: Hepatotoxicity with jaundice and acute hepatic failure.
Neurological: Dizziness, peripheral neuropathy, cerebral oedema (rare).
ADVERSE EFFECTS: MONITORING
Routine tests as per generic MDR-TB treatment monitoring guidelines.
INTERACTIONS
Streptomycin: Possible increased ototoxicty.
This information is not inclusive of all drug interactions. Please discuss with a pharmacist.
CONTRA-INDICATIONS & CAUTIONS
Contraindications:
HIV co-infection: Causes fatal skin rashes.
Prothionamide resistance: Risk of cross-resistance
NB: Thioacetazone is poorly tolerated by people of Asian or European origin. It is surprisingly well tolerated in East African countries and in South America. Consequently Thioacetazone is not routinely used by any of the TB programs we know in Cambodia, Lao PDR, Vietnam and China. Even in people of African or South American ethnicity, its use should be avoided in patients with HIV co-infection.
LABORATORY INFORMATION
Please find up to date information at www.assayfinder.com regarding individual providers of drug level monitoring tests. Click on the provider to discover contact details. Turnaround time varies depending on the test and whether it is run locally or sent to an external lab. By contacting laboratories in advance, turnaround time can significantly be reduced.
Thioacetazone is not usually recommended for the treatment of MDRTB. When it is used, it should be counted as half a drug in a treatment regimen.
DOSAGE
Adults: 150mg once daily.
Children: No information.
PREPARATIONS
Not currently available in the UK.
DRUG LEVEL MONITORING
· Drug levels need not be routinely measured.
ADVERSE EFFECTS
COMMON:
Dermatological: Rash (3%).
Gastrointestinal: Nausea, vomiting, diarrhoea, anorexia & dyspepsia.
Neurological: Giddiness (10%).
SERIOUS:
Haematological: Neutropaenia, anaemia, thrombocytopaenia; rarely: haemolytic anaemia, agranulocytosis, aplastic anaemia.
Hepatic: Hepatotoxicity with jaundice and acute hepatic failure.
Neurological: Dizziness, peripheral neuropathy, cerebral oedema (rare).
ADVERSE EFFECTS: MONITORING
Routine tests as per generic MDR-TB treatment monitoring guidelines.
INTERACTIONS
Streptomycin: Possible increased ototoxicty.
This information is not inclusive of all drug interactions. Please discuss with a pharmacist.
CONTRA-INDICATIONS & CAUTIONS
Contraindications:
HIV co-infection: Causes fatal skin rashes.
Prothionamide resistance: Risk of cross-resistance
NB: Thioacetazone is poorly tolerated by people of Asian or European origin. It is surprisingly well tolerated in East African countries and in South America. Consequently Thioacetazone is not routinely used by any of the TB programs we know in Cambodia, Lao PDR, Vietnam and China. Even in people of African or South American ethnicity, its use should be avoided in patients with HIV co-infection.
LABORATORY INFORMATION
Please find up to date information at www.assayfinder.com regarding individual providers of drug level monitoring tests. Click on the provider to discover contact details. Turnaround time varies depending on the test and whether it is run locally or sent to an external lab. By contacting laboratories in advance, turnaround time can significantly be reduced.
